Antibodies to m-csf

Abstract

The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

1 - 34 . (canceled) 
     
     
         35 . A monoclonal antibody or an antigen-binding portion thereof that specifically binds to M-CSF, wherein the antibody comprises a heavy chain amino acid sequence that is at least 90% identical to the heavy chain amino acid sequence of SEQ ID NO: 30 without the signal sequence. 
     
     
         36 . The monoclonal antibody or antigen-binding portion according to  claim 35 , wherein the antibody further comprises a light chain amino acid sequence of SEQ ID NO: 32 without the signal sequence. 
     
     
         37 . The monoclonal antibody or antigen-binding portion according to  claim 35 , wherein the heavy chain comprises an amino acid sequence that is at least 95% identical to the heavy chain amino acid sequence of SEQ ID NO: 30 without the signal sequence. 
     
     
         38 . A pharmaceutical composition, comprising the antibody or antigen-binding portion according to  claim 35  and a pharmaceutically acceptable carrier. 
     
     
         39 . The monoclonal antibody or antigen-binding portion according to  claim 37 , wherein the heavy chain comprises an amino acid sequence that is at least 99% identical to the heavy chain amino acid sequence of SEQ ID NO: 30 without the signal sequence. 
     
     
         40 . An isolated cell line that produces the antibody or antigen-binding portion according to  claim 36 , or the heavy chain or light chain of said antibody. 
     
     
         41 . The antigen-binding portion according to  claim 35 , wherein the portion is selected from the group consisting of: an Fab fragment, an F(ab′) 2  fragment, and an Fv fragment. 
     
     
         42 . A monoclonal antibody or an antigen-binding portion thereof that specifically binds to M-CSF, wherein the antibody comprises a light chain amino acid sequence that is at least 90% identical to the light chain amino acid sequence of SEQ ID NO: 32 without the signal sequence. 
     
     
         43 . The monoclonal antibody or antigen-binding portion according to  claim 42 , wherein the antibody further comprises a heavy chain amino acid sequence of SEQ ID NO: 30 without the signal sequence. 
     
     
         44 . The monoclonal antibody or antigen-binding portion according to  claim 42 , wherein the light chain comprises an amino acid sequence that is at least 95% identical to the light chain amino acid sequence of SEQ ID NO: 32 without the signal sequence. 
     
     
         45 . A pharmaceutical composition, comprising the antibody or antigen-binding portion according to  claim 42  and a pharmaceutically acceptable carrier. 
     
     
         46 . The monoclonal antibody or antigen-binding portion according to  claim 44 , wherein the light chain comprises an amino acid sequence that is at least 99% identical to the light chain amino acid sequence of SEQ ID NO: 32 without the signal sequence. 
     
     
         47 . An isolated cell line that produces the antibody or antigen-binding portion according to  claim 43 , or the heavy chain or light chain of said antibody. 
     
     
         48 . The antigen-binding portion according to  claim 42 , wherein the portion is selected from the group consisting of: an Fab fragment, an F(ab′) 2  fragment, and an Fv fragment. 
     
     
         49 . A monoclonal antibody or an antigen-binding portion thereof that specifically binds to M-CSF, wherein the antibody comprises a heavy chain amino acid sequence that is at least 90% identical to the heavy chain amino acid sequence of monoclonal antibody 8.10.3F. 
     
     
         50 . The monoclonal antibody or antigen-binding portion according to  claim 49 , wherein the antibody further comprises a light chain amino acid sequence of monoclonal antibody 8.10.3F. 
     
     
         51 . The monoclonal antibody or antigen-binding portion according to  claim 49 , wherein the heavy chain comprises an amino acid sequence that is at least 95% identical to the heavy chain amino acid sequence of monoclonal antibody 8.10.3F. 
     
     
         52 . A pharmaceutical composition, comprising the antibody or antigen-binding portion according to  claim 49  and a pharmaceutically acceptable carrier. 
     
     
         53 . The monoclonal antibody or antigen-binding portion according to  claim 51 , wherein the heavy chain comprises an amino acid sequence that is at least 99% identical to the heavy chain amino acid sequence of monoclonal antibody 8.10.3F. 
     
     
         54 . An isolated cell line that produces the antibody or antigen-binding portion according to  claim 50 , or the heavy chain or light chain of said antibody. 
     
     
         55 . The antigen-binding portion according to  claim 49 , wherein the portion is selected from the group consisting of: an Fab fragment, an F(ab′) 2  fragment, and an Fv fragment. 
     
     
         56 . A monoclonal antibody or an antigen-binding portion thereof that specifically binds to M-CSF, wherein the antibody comprises a light chain amino acid sequence that is at least 90% identical to the light chain amino acid sequence of monoclonal antibody 8.10.3F. 
     
     
         57 . The monoclonal antibody or antigen-binding portion according to  claim 56 , wherein the antibody further comprises a heavy chain amino acid sequence of monoclonal antibody 8.10.3F. 
     
     
         58 . The monoclonal antibody or antigen-binding portion according to  claim 56 , wherein the light chain comprises an amino acid sequence that is at least 95% identical to the light chain amino acid sequence of monoclonal antibody 8.10.3F. 
     
     
         59 . A pharmaceutical composition, comprising the antibody or antigen-binding portion according to  claim 56  and a pharmaceutically acceptable carrier. 
     
     
         60 . The monoclonal antibody or antigen-binding portion according to  claim 58 , wherein the light chain comprises an amino acid sequence that is at least 99% identical to the light chain amino acid sequence of monoclonal antibody 8.10.3F. 
     
     
         61 . An isolated cell line that produces the antibody or antigen-binding portion according to  claim 57 , or the heavy chain or light chain of said antibody. 
     
     
         62 . The antigen-binding portion according to  claim 56 , wherein the portion is selected from the group consisting of: an Fab fragment, an F(ab′) 2  fragment, and an Fv fragment.